New Brunswick-based Johnson & Johnson announced it has successfully completed its acquisition of Aragon Pharmaceuticals Inc. The deal closed for $650 million in cash upfront, with the potential for an additional $350 million in future milestone payments, spokesman Al Wasilewski said today.
Those numbers mirror what was first reported on the acquisition in June.
Development of compounds from Aragon's androgen receptor antagonist program, including its lead androgen receptor signaling inhibitor, ARN-509, will be managed by Janssen Research & Development LLC.
Digital content editor Joe Ross is @joeross on Twitter.